BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

92 related articles for article (PubMed ID: 7729732)

  • 1. Loop electrosurgical excision procedure for intensified cytoreduction of ovarian cancer.
    Fanning J; Hilgers RD
    Gynecol Oncol; 1995 May; 57(2):188-90. PubMed ID: 7729732
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Feasibility of laparoscopic debulking with electrosurgical loop excision procedure and argon beam coagulator at recurrence in patients with previous laparotomy debulking.
    Trinh H; Ott C; Fanning J
    Am J Obstet Gynecol; 2004 May; 190(5):1394-7. PubMed ID: 15167847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer.
    Bristow RE; Montz FJ; Lagasse LD; Leuchter RS; Karlan BY
    Gynecol Oncol; 1999 Mar; 72(3):278-87. PubMed ID: 10053096
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Full-thickness diaphragmatic resection with simple and secure closure to accomplish complete cytoreductive surgery for patients with ovarian cancer.
    Silver DF
    Gynecol Oncol; 2004 Nov; 95(2):384-7. PubMed ID: 15491761
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Splenectomy during secondary cytoreduction for ovarian cancer disease recurrence: surgical and survival data.
    Manci N; Bellati F; Muzii L; Calcagno M; Alon SA; Pernice M; Angioli R; Panici PB
    Ann Surg Oncol; 2006 Dec; 13(12):1717-23. PubMed ID: 16957965
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Secondary cytoreductive surgery for localized intra-abdominal recurrences in epithelial ovarian cancer.
    Munkarah A; Levenback C; Wolf JK; Bodurka-Bevers D; Tortolero-Luna G; Morris RT; Gershenson DM
    Gynecol Oncol; 2001 May; 81(2):237-41. PubMed ID: 11330956
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Complete surgical cytoreduction of advanced ovarian carcinoma using the argon beam coagulator.
    Bristow RE; Montz FJ
    Gynecol Oncol; 2001 Oct; 83(1):39-48. PubMed ID: 11585412
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved optimal cytoreduction rates for stages IIIC and IV epithelial ovarian, fallopian tube, and primary peritoneal cancer: a change in surgical approach.
    Chi DS; Franklin CC; Levine DA; Akselrod F; Sabbatini P; Jarnagin WR; DeMatteo R; Poynor EA; Abu-Rustum NR; Barakat RR
    Gynecol Oncol; 2004 Sep; 94(3):650-4. PubMed ID: 15350354
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Splenectomy and surgical cytoreduction for ovarian cancer.
    Chen LM; Leuchter RS; Lagasse LD; Karlan BY
    Gynecol Oncol; 2000 Jun; 77(3):362-8. PubMed ID: 10831343
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Complete cytoreductive surgery is feasible and maximizes survival in patients with advanced epithelial ovarian cancer: a prospective study.
    Eisenkop SM; Friedman RL; Wang HJ
    Gynecol Oncol; 1998 May; 69(2):103-8. PubMed ID: 9600815
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The impact of bulky upper abdominal disease cephalad to the greater omentum on surgical outcome for stage IIIC epithelial ovarian, fallopian tube, and primary peritoneal cancer.
    Zivanovic O; Eisenhauer EL; Zhou Q; Iasonos A; Sabbatini P; Sonoda Y; Abu-Rustum NR; Barakat RR; Chi DS
    Gynecol Oncol; 2008 Feb; 108(2):287-92. PubMed ID: 17996927
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [How to increase the optimal rate of secondary cytoreductive surgery in recurrent epithelial ovarian cancer].
    Li YF; Li MD; Liu FY; Liu JH; Li JD
    Ai Zheng; 2003 Nov; 22(11):1193-6. PubMed ID: 14613651
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Secondary cytoreductive surgery for isolated nodal recurrence in patients with epithelial ovarian cancer.
    Santillan A; Karam AK; Li AJ; Giuntoli R; Gardner GJ; Cass I; Karlan BY; Bristow RE
    Gynecol Oncol; 2007 Mar; 104(3):686-90. PubMed ID: 17141302
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The addition of extensive upper abdominal surgery to achieve optimal cytoreduction improves survival in patients with stages IIIC-IV epithelial ovarian cancer.
    Eisenhauer EL; Abu-Rustum NR; Sonoda Y; Levine DA; Poynor EA; Aghajanian C; Jarnagin WR; DeMatteo RP; D'Angelica MI; Barakat RR; Chi DS
    Gynecol Oncol; 2006 Dec; 103(3):1083-90. PubMed ID: 16890277
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tumor residual after surgical cytoreduction in prediction of clinical outcome in stage IV epithelial ovarian cancer: a Gynecologic Oncology Group Study.
    Winter WE; Maxwell GL; Tian C; Sundborg MJ; Rose GS; Rose PG; Rubin SC; Muggia F; McGuire WP;
    J Clin Oncol; 2008 Jan; 26(1):83-9. PubMed ID: 18025437
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Complete salvage surgical cytoreduction improves further survival of patients with late recurrent ovarian cancer.
    Gadducci A; Iacconi P; Cosio S; Fanucchi A; Cristofani R; Riccardo Genazzani A
    Gynecol Oncol; 2000 Dec; 79(3):344-9. PubMed ID: 11104603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases.
    Naik R; Nordin A; Cross PA; Hemming D; de Barros Lopes A; Monaghan JM
    Gynecol Oncol; 2000 Aug; 78(2):171-5. PubMed ID: 10926798
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Recurrent ovarian carcinoma of low malignant potential: the role of secondary surgical cytoreduction and the prognosis in Chinese patients.
    Zang RY; Yang WT; Shi DR; Xing Y; Cai SM
    J Surg Oncol; 2005 Jul; 91(1):67-72. PubMed ID: 15999350
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Loop electrosurgical excision procedure (LEEP) at Maharaj Nakorn Chiang Mai Hospital: problems in pathologic evaluation.
    Khunamornpong S; Raungrongmorakot K; Siriaunkgul S
    J Med Assoc Thai; 2001 Apr; 84(4):507-14. PubMed ID: 11460961
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic significance of CA-125 in the management of patients with recurrent epithelial ovarian carcinoma selected for secondary cytoreduction.
    Mahner S; Woelber L; Jung S; Eulenburg CZ; Ihnen M; Schwarz J; Sehouli J; Jaenicke F
    Anticancer Res; 2009 Jul; 29(7):2817-21. PubMed ID: 19596967
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.